Explore ARA-290 (cibinetide) dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
ARA-290 (cibinetide) is an 11-amino-acid peptide derived from a non-erythropoietic helix-B region of erythropoietin, studied for its tissue-protective and anti-inflammatory effects without the red-cell-stimulating activity of EPO. This data captures the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when setting up their ARA-290 reconstitution protocol.
ARA-290 — also known as cibinetide — is an 11-amino-acid peptide derived from the helix-B region of erythropoietin, designed by the Anthony Cerami group at Araim Pharmaceuticals (founded as the spinout from the original Kenneth Brines / Michael Brines tissue-protective EPO work) to retain EPO's tissue-protective signaling while removing the red-cell-stimulating activity that limits EPO's clinical use. The molecular logic is unusually clean: EPO's erythropoietic effect requires homodimeric EPOR-EPOR receptor binding, while its tissue-protective effect signals through a separate heteromeric "innate repair receptor" (IRR) composed of EPOR and the beta-common receptor (CD131); cibinetide was engineered to bind the IRR without activating the EPOR homodimer.
ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin, most often sourced for neuropathic-pain and tissue-repair research. It was engineered to keep EPO's tissue-protective signal without raising red-blood-cell counts. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
Cibinetide binds the innate-repair receptor (IRR), a heteromeric receptor formed by the EPO receptor and the β-common (CD131) receptor. IRR activation is anti-inflammatory and tissue-protective but, critically, does not engage the homodimeric EPO-receptor complex that drives erythropoiesis — so the molecule does not raise hematocrit or red-blood-cell mass at therapeutic doses.
A Phase 2 trial in sarcoidosis-associated small-fiber neuropathy (Heij et al., Mol Med 2017) reported improvements in neuropathic pain and small-fiber metrics versus placebo after 28 days. Additional Phase 2 work in chronic neuropathic pain, ophthalmologic dry-eye disease, and diabetic macular edema has been reported by Araim, with mixed results across endpoints.
ARA-290 has a reported half-life of ~2 min (plasma), and the dose intervals researchers model most often fall around once daily. Disappears from the blood within minutes, so there is no buildup at all. The benefit comes from triggering a longer-lasting tissue response, not from a steady blood level. It is catalogued under Recovery Peptides on WPA.
293 ARA-290 reconstitution calculations have been logged by the WPA community. The most common dose entered is 4mg (129 calculations). The median dose across all sessions is 2.5mg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (196 sessions). The most common dosing frequency is daily (7x/week) (23 logged protocols), followed by once weekly (12).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.